Skip to contentY
Yubo International Biotech Ltd
Y
YBGJYubo International Biotech Ltd Q3 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2023 Net Income-$621.05K-$621.05KN/M vs Q3 2023 EPS Diluted-$0.01-$0.01— vs Q3 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Yubo International Biotech Ltd · CIK 895464 · Engraved from SEC EDGAR
Operating Cash Flowderived-$92,613N/M ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end